Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16305812 | 0.94 | PLG (0.45) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16306068 | 0.92 | KIFC1 (0.45) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16305936 | 0.92 | KLKB1 (0.44) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16305928 | 0.92 | KLKB1 (0.44) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16305799 | 0.91 | PPARG (0.45) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16305689 | 0.91 | PPARG (0.45) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16306212 | 0.90 | ITGB3 (0.51) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16305802 | 0.90 | ITGB3 (0.51) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL15037075 | 0.90 | ITGB3 (0.47) | PLGITGB3ITGA2BKLKB1ITGB1 | |
| SCHEMBL16305793 | 0.90 | ITGB3 (0.50) | PLGITGB3ITGA2BKLKB1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
| WO-2014201172-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885ITGB3 4025/4885ITGA2B 4142/4885 |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885ITGB3 4025/4885ITGA2B 4142/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885ITGB3 4025/4885ITGA2B 4142/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885ITGB3 4025/4885ITGA2B 4142/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | PLG 2930/4885ITGB3 3678/4885ITGA2B 4134/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | PLG 2930/4885ITGB3 3678/4885ITGA2B 4134/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885ITGB3 4025/4885ITGA2B 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.